{"id":"cilostazol-probucol-group","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL799","moleculeType":"Small molecule","molecularWeight":"369.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cilostazol is a phosphodiesterase-3 inhibitor that increases cAMP in platelets and vascular smooth muscle, promoting vasodilation and inhibiting platelet aggregation. Probucol is a lipophilic antioxidant that reduces LDL cholesterol oxidation and has antiatherosclerotic properties. Together, they work synergistically to improve peripheral circulation and reduce thrombotic risk.","oneSentence":"This combination drug inhibits platelet aggregation and reduces cholesterol oxidation to improve blood flow and reduce cardiovascular events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:30:01.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent claudication and peripheral arterial disease"},{"name":"Atherosclerotic cardiovascular disease prevention"}]},"trialDetails":[{"nctId":"NCT00823849","phase":"PHASE4","title":"Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-10","conditions":"Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans","enrollment":200},{"nctId":"NCT01142284","phase":"PHASE2","title":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-05-19","conditions":"Peripheral Artery Disease","enrollment":80},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":"Hyperlipidemias","enrollment":342},{"nctId":"NCT01013532","phase":"PHASE4","title":"PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2009-06","conditions":"Brain Ischemia, Intracranial Hemorrhages","enrollment":1600},{"nctId":"NCT01031667","phase":"PHASE4","title":"Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-11","conditions":"Therapy","enrollment":118},{"nctId":"NCT00823875","phase":"PHASE4","title":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":"Atherosclerosis Cerebral Infarction","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pletaal and Changtai"],"phase":"marketed","status":"active","brandName":"Cilostazol + Probucol group","genericName":"Cilostazol + Probucol group","companyName":"Otsuka Beijing Research Institute","companyId":"otsuka-beijing-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug inhibits platelet aggregation and reduces cholesterol oxidation to improve blood flow and reduce cardiovascular events. Used for Intermittent claudication and peripheral arterial disease, Atherosclerotic cardiovascular disease prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}